PL2470671T3 - Przeciwciała antykinowe wiążące się z wieloma chemokinami CC - Google Patents
Przeciwciała antykinowe wiążące się z wieloma chemokinami CCInfo
- Publication number
- PL2470671T3 PL2470671T3 PL10812667T PL10812667T PL2470671T3 PL 2470671 T3 PL2470671 T3 PL 2470671T3 PL 10812667 T PL10812667 T PL 10812667T PL 10812667 T PL10812667 T PL 10812667T PL 2470671 T3 PL2470671 T3 PL 2470671T3
- Authority
- PL
- Poland
- Prior art keywords
- chemokines
- bind
- antikine antibodies
- antikine
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23801509P | 2009-08-28 | 2009-08-28 | |
PCT/US2010/047004 WO2011025962A1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
EP20100812667 EP2470671B1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2470671T3 true PL2470671T3 (pl) | 2015-05-29 |
Family
ID=43628404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10812667T PL2470671T3 (pl) | 2009-08-28 | 2010-08-27 | Przeciwciała antykinowe wiążące się z wieloma chemokinami CC |
Country Status (18)
Country | Link |
---|---|
US (3) | US8313747B2 (pl) |
EP (1) | EP2470671B1 (pl) |
JP (2) | JP6109571B2 (pl) |
KR (1) | KR101778813B1 (pl) |
CN (1) | CN102782148B (pl) |
AU (1) | AU2010286516B2 (pl) |
BR (1) | BR112012004387A2 (pl) |
CA (1) | CA2771781C (pl) |
DK (1) | DK2470671T3 (pl) |
ES (1) | ES2531561T3 (pl) |
HR (1) | HRP20150162T1 (pl) |
IN (1) | IN2012DN01769A (pl) |
MX (1) | MX2012002427A (pl) |
PL (1) | PL2470671T3 (pl) |
PT (1) | PT2470671E (pl) |
SI (1) | SI2470671T1 (pl) |
SM (1) | SMT201500011B (pl) |
WO (1) | WO2011025962A1 (pl) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6109571B2 (ja) * | 2009-08-28 | 2017-04-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 複数種のCCケモカインと結合するantikine抗体 |
DK2717941T3 (da) * | 2011-06-13 | 2020-07-13 | Tla Targeted Immunotherapies Ab | Behandling af cancer |
WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
WO2013036290A1 (en) * | 2011-09-09 | 2013-03-14 | Yale University | Compositions and methods for assessing and treating inflammatory diseases and disorders |
CN104662044B (zh) | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
JO3580B1 (ar) * | 2013-03-15 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لكيموكين elr+ cxc شامل |
MX371412B (es) | 2013-05-23 | 2020-01-29 | Shire Human Genetic Therapies | ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A LOXL2 Y ccl.2, COMPOSICIONES DE LOS MISMOS, Y SU USO EN EL TRATAMIENTO DE ESCLERODERMIA. |
JP6220222B2 (ja) * | 2013-10-28 | 2017-10-25 | シスメックス株式会社 | 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品 |
EP3611191A1 (en) * | 2013-12-09 | 2020-02-19 | Allakos Inc. | Anti-siglec-8 antibodies and methods of use thereof |
AU2015222757B2 (en) | 2014-02-28 | 2020-10-08 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
EP3114139B1 (en) * | 2014-03-04 | 2022-06-15 | Chemomab Ltd. | Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines |
CN104198727A (zh) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法 |
TWI576112B (zh) * | 2014-10-24 | 2017-04-01 | 國立陽明大學 | 巨噬細胞發炎蛋白-1β(MIP-1β)抑制劑用以保護胰臟及防止血糖升高的用途 |
RU2711729C2 (ru) | 2014-12-09 | 2020-01-21 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, имеющие гуманизированный ген кластера дифференцировки 274 |
US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
IL299099A (en) | 2016-06-27 | 2023-02-01 | Univ California | Combinations of cancer treatments |
EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2018159787A1 (ja) * | 2017-03-01 | 2018-09-07 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
RU2740438C1 (ru) * | 2017-04-05 | 2021-01-14 | Корея Рисерч Инститьют Оф Байосайенс Энд Байотекнолоджи | Активирующий nk-клетки слитый белок, nk-клетки и фармацевтическая композиция, включающая их |
US11203638B2 (en) | 2017-05-05 | 2021-12-21 | Allakos Inc. | Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis |
WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
WO2019075472A1 (en) * | 2017-10-13 | 2019-04-18 | A&G Pharmaceutical, Inc. | MONOCLONAL AND CONJUGATED ANTIBODIES AGAINST THE PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF |
WO2019133902A2 (en) * | 2017-12-28 | 2019-07-04 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
WO2019165397A1 (en) * | 2018-02-26 | 2019-08-29 | Cornell University | Quantitative biomarkers of ehv-1 susceptibility and protection |
WO2019217705A1 (en) * | 2018-05-11 | 2019-11-14 | Proplex Technologies, LLC | Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
CN110117329B (zh) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
US20220356238A1 (en) * | 2019-07-02 | 2022-11-10 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
KR102489282B1 (ko) * | 2019-07-02 | 2023-01-17 | 고려대학교 산학협력단 | Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물 |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
CN113893331A (zh) * | 2020-07-06 | 2022-01-07 | 中国农业科学院特产研究所 | 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用 |
EP4178614A2 (en) * | 2020-07-08 | 2023-05-17 | Georgia Tech Research Corporation | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection |
CA3198647A1 (en) * | 2020-10-16 | 2022-04-21 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
CN115598111A (zh) * | 2021-07-08 | 2023-01-13 | 南京大学(Cn) | 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法 |
CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ES2301158T3 (es) * | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
RS20050834A (en) | 2002-08-19 | 2007-12-31 | Abgenix Inc., | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
WO2004050836A2 (en) | 2002-11-27 | 2004-06-17 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
AU2005318173B2 (en) * | 2004-12-21 | 2011-05-12 | Merck Serono Sa | CC-chemokine antagonists |
DK2185719T3 (en) * | 2007-08-02 | 2014-02-17 | Novimmune Sa | ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF |
JP6109571B2 (ja) * | 2009-08-28 | 2017-04-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 複数種のCCケモカインと結合するantikine抗体 |
-
2010
- 2010-08-27 JP JP2012527033A patent/JP6109571B2/ja active Active
- 2010-08-27 SI SI201030901T patent/SI2470671T1/sl unknown
- 2010-08-27 DK DK10812667T patent/DK2470671T3/en active
- 2010-08-27 US US12/870,573 patent/US8313747B2/en active Active
- 2010-08-27 KR KR1020127007885A patent/KR101778813B1/ko active IP Right Grant
- 2010-08-27 IN IN1769DEN2012 patent/IN2012DN01769A/en unknown
- 2010-08-27 PT PT10812667T patent/PT2470671E/pt unknown
- 2010-08-27 ES ES10812667.3T patent/ES2531561T3/es active Active
- 2010-08-27 WO PCT/US2010/047004 patent/WO2011025962A1/en active Application Filing
- 2010-08-27 PL PL10812667T patent/PL2470671T3/pl unknown
- 2010-08-27 BR BR112012004387A patent/BR112012004387A2/pt active Search and Examination
- 2010-08-27 AU AU2010286516A patent/AU2010286516B2/en active Active
- 2010-08-27 CA CA2771781A patent/CA2771781C/en active Active
- 2010-08-27 CN CN201080048961.XA patent/CN102782148B/zh not_active Expired - Fee Related
- 2010-08-27 MX MX2012002427A patent/MX2012002427A/es active IP Right Grant
- 2010-08-27 EP EP20100812667 patent/EP2470671B1/en active Active
-
2012
- 2012-10-22 US US13/657,120 patent/US9005617B2/en active Active
-
2015
- 2015-01-16 SM SM201500011T patent/SMT201500011B/xx unknown
- 2015-02-10 HR HRP20150162TT patent/HRP20150162T1/hr unknown
- 2015-02-24 US US14/630,112 patent/US20150166647A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011829A patent/JP2016135783A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20130108640A1 (en) | 2013-05-02 |
JP2013503192A (ja) | 2013-01-31 |
PT2470671E (pt) | 2015-02-05 |
KR20120091013A (ko) | 2012-08-17 |
EP2470671A4 (en) | 2013-04-03 |
DK2470671T3 (en) | 2015-02-09 |
US8313747B2 (en) | 2012-11-20 |
JP6109571B2 (ja) | 2017-04-05 |
AU2010286516A2 (en) | 2012-06-14 |
US20150166647A1 (en) | 2015-06-18 |
CA2771781A1 (en) | 2011-03-03 |
AU2010286516B2 (en) | 2016-10-06 |
CN102782148B (zh) | 2016-04-20 |
CN102782148A (zh) | 2012-11-14 |
US20110059107A1 (en) | 2011-03-10 |
IN2012DN01769A (pl) | 2015-06-05 |
EP2470671B1 (en) | 2014-12-24 |
JP2016135783A (ja) | 2016-07-28 |
RU2012111820A (ru) | 2013-10-10 |
AU2010286516A1 (en) | 2012-03-08 |
WO2011025962A1 (en) | 2011-03-03 |
US9005617B2 (en) | 2015-04-14 |
EP2470671A1 (en) | 2012-07-04 |
SMT201500011B (it) | 2015-03-05 |
SI2470671T1 (sl) | 2015-04-30 |
MX2012002427A (es) | 2012-08-03 |
CA2771781C (en) | 2019-01-15 |
HRP20150162T1 (hr) | 2015-05-08 |
BR112012004387A2 (pt) | 2015-09-08 |
ES2531561T3 (es) | 2015-03-17 |
KR101778813B1 (ko) | 2017-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2470671A4 (en) | ANTIBODY ANTIBODIES BINDING TO MULTIPLE CC CHEMOKINES | |
HRP20190047T1 (hr) | Protutijela koja se vežu na csf1r | |
HK1217711A1 (zh) | 特異於鈣粘素- 的抗體 | |
IL214996A0 (en) | Anti-bcma antibodies | |
GB0920127D0 (en) | Antibodies | |
ZA201202329B (en) | Antibodies that specifically bind to the epha2 receptor | |
ZA201104545B (en) | Anti-siglec-15 antibody | |
GB0909906D0 (en) | Antibodies | |
EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
GB0920324D0 (en) | Antibodies | |
GB2473934B (en) | Anti-VEEV antibody | |
EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
EP2424892A4 (en) | DC-STAMP ANTIBODY | |
EP2524964A4 (en) | FOR THE ACTIVATED EGFR SPECIFIC ANTIBODY | |
GB0911712D0 (en) | Antibody | |
GB0908945D0 (en) | Antibodies |